The goal of analysing PRO-AE data is to add to the knowledge already provided by HCPs, when available, increasing the likelihood and speed of detection of signals.
However, these studies were performed with the major goal of analysing the engraftment, viability and functionality of human EHTs after transplantation into immune-suppressed animals, and not in respect of the establishment of models for drug screening or safety pharmacology.
Thus, split-TEV assays represent an alternative option towards the goal of analysing regulated PPIs of full-length proteins within signaling cascades that occur both at the membrane and in the cytosol of living cells (this study and [ 5]).
The goal of analysing auditory ERPs in individual children is complicated by the fact that at fast presentation rates, N1 and P2 peaks are often not seen in ERPs of children under 12 years of age (Albrecht, von Suchodoletz & Uwer, 2000; Ponton, Eggermont, Kwong & Don, 2000).
Choosing between a marginal or multilevel model depends on the goals of the analyses.
The main goals of these analyses were to explain response variability (i.e. bioenergetic plasticity) and to characterize quantitatively the influence of the major explanatory factor(s).
The choice of allele frequencies to be used may depend upon the goals of the analyses [ 20] but the effect of this choice on the results of genomic evaluation is still an open issue, particularly in the multi-breed context.
One of the main goals of our analyses is to select potential SMAD interacting transcription factors from a large feature space (>150 transcription factors from Transfac database) in order to build SMAD modules.
The goals of these analyses were to identify genes and physiological pathways that establish cotton stems and roots as physiological sinks and investigate the role these pathways play in cotton development during seed set.
The primary goals of the analyses were to (i) understand the impact of patient characteristics on the PK and PD of evacetrapib; (ii) characterize the relationship between evacetrapib exposure and changes in HDL-C and LDL-C; and (iii) understand the impact of statin coadministration on the PK and PD of evacetrapib.
